Download APSHO's free guide, 'Conference Hacks: Maximizing Your Exhibit Hall Experience,' for expert tips on navigating exhibit halls, networking, and staying updated on the latest technologies. Click below to get yours!
| Understanding Antibody-Drug Conjugates |
|
In this Educator Module, Amber B. Clemmons, PharmD, BCOP, FHOPA, of University of Georgia College of Pharmacy and Wellstar-MCG Health, and Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP, of Rutgers Cancer Institute, provide a comprehensive overview of the mechanisms of action of antibody-drug conjugate (ADC) therapy, focusing on how molecular design influences toxicity profiles and patient selection criteria. They take a deep dive into the monitoring and management of common toxicities associated with ADCs, using real-world case studies to showcase best practices. Funding and support provided by AstraZeneca, Kite, a Gilead Company, Pfizer, and Astellas
Take a short survey and earn your certificate of participation!
APSHO members: Login here APSHO non-members: Create an APSHO guest non-member profile first by clicking here. Once you’ve created your APSHO profile, follow the prompts to the survey and the certificate. Additional Resources
Meet The Faculty
Amber B. Clemmons, PharmD, BCOP, FHOPA
University of Georgia College of Pharmacy and Wellstar-MCG Health Amber B. Clemmons, PharmD, BCOP, FHOPA, is a clinical professor at the University of Georgia College of Pharmacy and clinical pharmacy specialist for the adult bone marrow transplantation (BMT)/malignant hematology team at Wellstar-MCG
Health. She also serves as the residency program director for the Oncology Pharmacy program. Dr. Clemmons received her Doctor of Pharmacy degree from the University of Michigan College of Pharmacy and completed a University of Georgia
College of Pharmacy Teaching Certificate and a Hematology/Oncology Pharmacy residency at the University of North Carolina. She is a highly active member of the Hematology Oncology Pharmacy Association (HOPA) and the American Society
for Transplantation and Cellular Therapy (ASTCT) Pharmacy Special Interest Group (SIG), as well as a member of the American Society of Health-System Pharmacists (ASHP), Georgia Society of Health-System Pharmacists (GSHP), and the Georgia
Cancer Center. Dr. Clemmons is highly recognized, has received multiple awards, and has achieved HOPA fellow status (FHOPA).
Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP
Rutgers Cancer Institute Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP, is a nurse practitioner in the GU Medical Oncology Group at Rutgers Cancer Institute. In her role, she manages patients on chemotherapy, oral oncolytics, bio/immunotherapy, antibody-drug conjugates
(ADCs), targeted therapies, and clinical trials, calling on her in-depth oncology-specific knowledge base for clinical decision capability. Ms. Kota initially joined Rutgers Cancer Institute as a nurse clinician in adult infusion and
then transferred to the Stacy Goldstein Breast Cancer Center. She moved into her current role after graduating from the nurse practitioner program at Drexel University. Her nursing experience includes medical oncology in community,
inpatient, and outpatient settings. Ms. Kota has been an author on several publications and is frequently engaged as an expert speaker in the identification and management of toxicities and adverse events from ADC therapy in oncology.
|
